Nurix enrolls first patient in Phase 1b/2 CLL trial of BTK degrader bexobrutideg plus venetoclax

• Nurix enrolled the first patient in a Phase 1b/2 study testing BTK degrader bexobrutideg with venetoclax in CLL/SLL.
• Trial results have not been presented; data are expected to guide future registrational development plans across CLL treatment lines.
• Initial focus is relapsed or refractory CLL, with potential expansion into first-line use if the combination shows acceptable safety and activity.
• Program sits within its Roche collaboration, with planned evaluation alongside selected Roche anti-CD20 antibodies in additional cohorts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070100PRIMZONEFULLFEED9840810) on October 07, 2026, and is solely responsible for the information contained therein.